Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8634024 | 0.94 | POLB (0.55) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL16902894 | 0.86 | LTA4H (0.48) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL833204 | 0.83 | POLB (0.56) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL27669789 | 0.83 | LTA4H (0.45) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL14449300 | 0.81 | POLB (0.59) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL31664416 | 0.81 | ACACB (0.48) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| Hydrogen Peroxide SCHEMBL28902806 | 0.80 | KMT2A (0.70) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL125543 | 0.80 | ALDH1A3 (0.64) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL5355098 | 0.79 | POLB (0.53) | POLBCYP1A2GAACYP2D6CYP2C19 | |
| SCHEMBL805120 | 0.79 | POLB (0.57) | POLBCYP1A2GAACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10233341-A | — | — | None | — | — | JP | disclosed |
| CN-114375291-B | Novel compounds for skin lightening | 联合利华知识产权控股有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-109206360-B | Carbazole amide derivative or salt thereof, and preparation method and application thereof | 复旦大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-114375291-A | Novel compounds for skin lightening | 联合利华知识产权控股有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114341100-A | Novel compounds for skin lightening | 联合利华知识产权控股有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11156874-B2 | Liquid crystal photoalignment agent and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-10-26 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3672960-A2 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-5135563-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-08-04 | — | — | US | disclosed |
| US-5129938-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0469711-A1 | Pyrimidine derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-02-05 | — | — | EP | disclosed |
| EP-0468690-A1 | Pyrimidine derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0457505-A2 | Pyrimidine derivatives and their use as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-11-21 | — | — | EP | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0093010-B1 | ALPHA-HYDROXYETHYLPHOSPHINATES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-06-11 | — | — | EP | disclosed |
| US-4554111-A | α-Hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-11-19 | — | — | US | disclosed |
| US-4544652-A | α-Hydroxyethylphosphinates, and their use as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-01 | — | — | US | disclosed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440884-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, VHL, CYP11B2 | POLB 1110/4885CYP1A2 355/4885GAA 37/4885 |
| US-20210122713-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, VHL, CYP11B2 | POLB 1110/4885CYP1A2 355/4885GAA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.